GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Medical Science Corp (XKRX:142280) » Definitions » Capex-to-Revenue

Green Cross Medical Science (XKRX:142280) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Green Cross Medical Science Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Green Cross Medical Science's Capital Expenditure for the three months ended in Dec. 2024 was ₩-124.33 Mil. Its Revenue for the three months ended in Dec. 2024 was ₩27,752.27 Mil.

Hence, Green Cross Medical Science's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


Green Cross Medical Science Capex-to-Revenue Historical Data

The historical data trend for Green Cross Medical Science's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Green Cross Medical Science Capex-to-Revenue Chart

Green Cross Medical Science Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.04 0.03 0.06 0.03

Green Cross Medical Science Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.03 0.04 0.05 -

Competitive Comparison of Green Cross Medical Science's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Green Cross Medical Science's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Green Cross Medical Science's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Green Cross Medical Science's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Green Cross Medical Science's Capex-to-Revenue falls into.


;
;

Green Cross Medical Science Capex-to-Revenue Calculation

Green Cross Medical Science's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3276.842) / 103852.287
=0.03

Green Cross Medical Science's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-124.333) / 27752.265
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Green Cross Medical Science  (XKRX:142280) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Green Cross Medical Science Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Green Cross Medical Science's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Green Cross Medical Science Business Description

Traded in Other Exchanges
N/A
Address
107, Ihyeon-ro 30beon-gil, Giheung-gu, Gyeonggi-do, Yongin-si, KOR, 16924
Green Cross Medical Science Corp is a total medical device company. It is engaged in the blood glucose business, kidney hemodialysis business, and blood bag business with the application of its know-how in in-vitro diagnostics. The product portfolio offered by the organization includes diagnostic reagents, diagnostic instruments, blood bag, home medical devices, blood dialysis products and HbA1c/BGMS.

Green Cross Medical Science Headlines

No Headlines